Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging - PubMed (original) (raw)
Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging
E C Unger et al. Radiology. 1989 Apr.
Abstract
Liposomal gadolinium diethylenetriaminepentaacetic acid (DTPA) encapsulated within 70- and 400-nm vesicles was tested as a contrast agent for magnetic resonance (MR) imaging of the liver in rats with hepatic metastases. Liposomal Gd-DTPA caused significant improvement in contrast between liver and tumor (P less than .005) on T1-weighted MR images. Smaller 70-nm liposomal Gd-DTPA vesicles caused greater contrast enhancement, reflecting the larger surface-area-to-volume ratio of the smaller vesicles. Liposomal Gd-DTPA-enhanced images permitted significant improvement in metastasis detection by five blinded radiologists (P less than .005). By comparison, free Gd-DTPA without liposomes caused a statistically significant reduction in contrast between tumor and liver and reduced lesion detection (P less than .01). Liposomal Gd-DTPA also resulted in sustained vascular enhancement for 1 hour after administration. The results suggest that paramagnetic liposomes may become a useful MR imaging contrast agent.
Similar articles
- Liposomal Gd-DTPA: preparation and characterization of relaxivity.
Tilcock C, Unger E, Cullis P, MacDougall P. Tilcock C, et al. Radiology. 1989 Apr;171(1):77-80. doi: 10.1148/radiology.171.1.2928549. Radiology. 1989. PMID: 2928549 - Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
Vogl TJ, Kümmel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, Schwarz W, Müller PK, Bechstein WO, Mack MG, Söllner O, Felix R. Vogl TJ, et al. Radiology. 1996 Jul;200(1):59-67. doi: 10.1148/radiology.200.1.8657946. Radiology. 1996. PMID: 8657946 Clinical Trial. - Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver.
Pavone P, Patrizio G, Buoni C, Tettamanti E, Passariello R, Musu C, Tirone P, Felder E. Pavone P, et al. Radiology. 1990 Jul;176(1):61-4. doi: 10.1148/radiology.176.1.2353112. Radiology. 1990. PMID: 2353112 - MR contrast enhancement of intracranial lesions with Gd-DTPA.
Hesselink JR, Press GA. Hesselink JR, et al. Radiol Clin North Am. 1988 Jul;26(4):873-87. Radiol Clin North Am. 1988. PMID: 3289078 Review. - Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A, Paci E. Giovagnoni A, et al. Magn Reson Imaging Clin N Am. 1996 Feb;4(1):61-72. Magn Reson Imaging Clin N Am. 1996. PMID: 8673717 Review.
Cited by
- Imaging and drug delivery using theranostic nanoparticles.
Janib SM, Moses AS, MacKay JA. Janib SM, et al. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1052-1063. doi: 10.1016/j.addr.2010.08.004. Epub 2010 Aug 13. Adv Drug Deliv Rev. 2010. PMID: 20709124 Free PMC article. Review. - A scale to measure MRI contrast agent sensitivity.
Alvares RDA, Szulc DA, Cheng HL. Alvares RDA, et al. Sci Rep. 2017 Nov 14;7(1):15493. doi: 10.1038/s41598-017-15732-8. Sci Rep. 2017. PMID: 29138455 Free PMC article. - MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.
Liu X, Madhankumar AB, Miller PA, Duck KA, Hafenstein S, Rizk E, Slagle-Webb B, Sheehan JM, Connor JR, Yang QX. Liu X, et al. Neuro Oncol. 2016 May;18(5):691-9. doi: 10.1093/neuonc/nov263. Epub 2015 Oct 31. Neuro Oncol. 2016. PMID: 26519740 Free PMC article. - Paramagnetic liposome nanoparticles for cellular and tumour imaging.
Kamaly N, Miller AD. Kamaly N, et al. Int J Mol Sci. 2010 Apr 15;11(4):1759-76. doi: 10.3390/ijms11041759. Int J Mol Sci. 2010. PMID: 20480040 Free PMC article. Review. - Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles.
Arms L, Smith DW, Flynn J, Palmer W, Martin A, Woldu A, Hua S. Arms L, et al. Front Pharmacol. 2018 Aug 14;9:802. doi: 10.3389/fphar.2018.00802. eCollection 2018. Front Pharmacol. 2018. PMID: 30154715 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical